US generics giant Mylan Pharmaceuticals (Mylan) and its partner, generics manufacturer Aspen Pharmacare Holdings (Aspen), announced on 4 December 2017 that it had launched generic Myleran (busulfan) single-dose vial in the US, after receiving final approval from the US Food and Drug Administration (FDA).
Mylan/Aspen launch generic busulfan injection
Generics/News
|
Posted 08/12/2017
0
Post your comment
Myleran is a generic version of Otsuka Pharmaceutical’s Busulfex Injection, which is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic haematopoietic progenitor cell transplantation for chronic myelogenous leukaemia.
As part of its partnership with Aspen, Mylan will commercialize Myleran, 60 mg/10 mL (6 mg/mL) single-dose vial in the US. Mylan has one of the largest injectable portfolios in the industry and is also one of the largest suppliers of cancer medicines by volume in the US.
US sales for Busulfex Injection, 60 mg/10 mL (6 mg/mL) single-dose vial were approximately US$97 million for the 12 months ending 30 September 2017, according to IQVIA.
Related articles
Mylan launches three HIV generics in Canada
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.
Source: Mylan
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment